hotspot -WSS

hotspot

author：knowledge 2025-09-05 13:32:53 - browse：33167

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Are infertility treatments 'essential' during the Covid

entertainment

WSS

The stock market has soared this year, but will it last? Experts weigh in

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

In same hospitals, Black patients receive fewer opioids than white patients

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

There’s a way to spot data fakery. All journals should be using it

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

At least 13 dead in Texas as scorching temps continue

Sanders wants to replace patents with prizes for drug inventions

Medicare proposal to cover medical devices draws a mixed reaction

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Walensky prepares to leave CDC — and Congress — behind

Drastic changes should bring profitability, startup health insurers say

Dobbs anniversary: the lost opportunity of abortion as health care

Naloxone nonprofit donates 200,000 doses after FDA approval

Wikipedia

Why failed clinical trials don’t always spell doom for a new drug

NIH trials fail to test meaningful long Covid therapies, experts say

Scientists grapple with ethics of stem cell research

How to use technology to prevent future drug shortages

What to know about Virgin Galactic's 1st mission taking paying customers to space

Telehealth startups are trying to fill the menopause care vacuum

hotspot

hotspot

entertainment

focus